Raf1, Aurora-A/STK15 and E-cadherin biomarkers expression in patients with pTa/pT1 urothelial bladder carcinoma; a retrospective TMA study of 246 patients with long-term follow-up

European Journal of Surgical Oncology

Volumn 32, Issue 4, 2006, Pages 439-444

  Mhawech Fauceglia, P ^a   Fischer, G ^a   Beck, A ^a   Cheney, R T ^a   Herrmann, F R ^b  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Aurora A; E CD; Protein immunohistochemical expression; pTa pT1 tumour behavior; Raf1

Indexed keywords

ANTINEOPLASTIC AGENT; AURORA A KINASE; BIOLOGICAL MARKER; RAF PROTEIN; UVOMORULIN;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; CYSTECTOMY; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; TISSUE MICROARRAY; UROGENITAL TRACT CANCER;

ADULT; AGED; AGED, 80 AND OVER; CADHERINS; CARCINOMA; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-RAF; RETROSPECTIVE STUDIES; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 33646201958     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2006.01.018     Document Type: Article

References (28)

1. Greenlee R.T., Hill-Harmon M.B., Murray T., and Thun M. Cancer Stat 51 (2001) 15-36
2. Borden Jr. L.S., Clark P.E., and Hall M.C. Bladder cancer. Curr Opin Oncol 17 (2005) 275-280
3. Holmang S., Hedelin H., Anderstrom C., Holmberg E., Busch C., and Johansson S.L. Recurrence and progression in low grade papillary urothelial tumors. J Urol 162 (1999) 702-707
4. Jordan A.M., Weigarten J., and Murphy W.M. Transitional cell neoplasms of the urinary bladder. Can biologic potential be predicted from histologic grade?. Cancer 60 (1987) 2766-2774
5. Hurst C.D., Fiegler H., Carr P., Williams S., Carter N.P., and Knowles M.A. High-resolution analysis of genomic copy number alterations in bladder cancer by micro-array comparative genomic hybridization. Oncogene 18 (2004) 2250-2256
6. Prat E., Bernues M., Caballin M.R., Egozcue J., Gelabert A., and Miro R. Detection of chromosomal imbalances in papillary bladder tumors by comparative genomic hybridization. Urology 57 (2001) 986-992
7. Richter J., Wagner U., Schmarl P., Maurer R., Alund G., Knonagel H., et al. Chromosomal imbalances are associated with a high risk of progression in early invasive (p1) urinary bladder cancer. Cancer Res 59 (1999) 5687-5691
8. Simon R., Richter J., Wagner U., Fijan A., Bruderer J., Schmid U., et al. High-throughput tissue microarray analysis of 3p25 (RAF1) and 8p12 (FGFR1) copy number alterations in urinary bladder cancer. Cancer Res 61 (2001) 4514-4519
9. Sen S., Zhou H., Zhang R.-D., Yoon DS., Vakar-Lopez F., Ito S., et al. Amplification/overexpression of a mitotic gene in human bladder cancer. J Natl Cancer Inst 94 (2002) 1320-1329
10. Sun W., and Herrera G.A. E-cadherin expression in urotehlial carcinoma in situ, superficial papillary transitional cell carcinoma, and invasive transitional cell carcinoma. Hum Pathol 33 (2002) 996-1000
11. Byrne R.R., Sahriat S.F., Brown R., Kattan MW., Morton R., Wheeler T., et al. E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastasis with long-term follow-up. J Urol 165 (2001) 1473-1479
12. Simon R., Mirlacher M., and Sauter G. Tissue microarrays. Biotechniques 36 (2004) 98-105
13. In: Sobin L.H., and Wittekind C. (Eds). TNM classification of malignant tumors. 6th ed (2002), Wiley, New York
14. Histological typing of urinary bladder tumors. In: Mostofi F.K., Sobin L.H., and Torloni H. (Eds). International classification of tumors, no. 10 (1973), World Health Organization, Geneva 15-36
15. Kononen J., Bubendorf L., Kallioniemi A., Barlund M., Schmarl P., Leighton S., et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4 (1998) 844-847
16. Nakopoulou L., Zervas A., Gakiopoulou-Givalou H., Constantininides C., Doumanis G., Davaris P., et al. Prognostic value of E-cadherin-catenin, P120ctn in patients with transitional cell bladder cancer. Anticancer Res 20 (2000) 4571-4578
17. Syrigos K.N., Karapanagiotou E., and Harrington K.J. The clinical significance of molecular markers to bladder cancer. Hybrid Hybridomics 23 (2004) 335-342
18. Sanchez-Carbayo M., Socci N.D., Charytonowicz E., Lu M., Prystowsky M., Childs G., et al. Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes. Cancer Res 62 (2002) 6973-6980
19. Imao T., Koshida K., Endo Y., Uchibayashi T., and Namiki M. Dominant role of E-cadherin in the progression of bladder cancer. J Urol 161 (1999) 692-698
20. Popov Z., Gil-Diez de Medina S., Lefrere-belda M.A., Hoznek A., Bastuji-Garin S., Abbou C., et al. Low E-cadherin expression in bladder cancer at the transcriptional and protein level provides prognostic information. Br J Cancer 83 (2000) 209-214
21. Zhou H., Kuang J., Zhong L., Kuo W.-L., Gray JW., Sahin A., et al. Tumour amplified kinase AURORA-A/BTAK induces centrosome amplification, aneuploidy, and transformation. Nature 20 (1998) 189-193
22. Stenoien D.L., Sen S., Mancini M.A., and Brinkley B.R. The centrosomal kinase Aurora-A/AURORA-A interacts with a putative tumor suppressor NM23-H1. Cell Motil Cytoskeleton 55 (2003) 134-146
23. Jeng Y.-M., Peng S.-Y., Lin C.-Y., and Hsu H.-C. Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clin Cancer Res 10 (2004) 2065-2071
24. Li D., Zhu J., Firozi P.F., Abbruzzese J., Evans D., Cleary K., et al. Overexpression of oncogeneic AURORA-A/BTAK/Aurora A kinase in human pancreatic cancer. Clin Cancer Res 9 (2003) 991-997
25. Hoque A., Crater J., Xia W., Hung M., Sahin A., Sen S., et al. Loss of aurora A/AURORA-A/BTAK overexpression correlates with transition of in situ to invasive ductal carcinoma of the breast. Cancer Epidemiol Biomarkers Prev 12 (2003) 1518-1522
26. Fraizer G.C., Diaz M.F., Lee I.L., Grossman H.B., and Sen S. Aurora-A/AURORA-A/BTAK enhances chromosomal instability in bladder cancer cells. Int J Oncol 25 (2004) 1631-1639
27. Yamamoto Y., Matsuyama H., Furuya T., Oga A., Yoshihoro S., Okuda M., et al. Centrosome hyperamplification predicts progression and tumor recurrence in bladder cancer. Clin Cancer Res 10 (2004) 6449-6455
28. Baccarini M. Second nature: biological functions of the Raf-1 'kinase'. Mini-review. FEBS 579 (2005) 3271-3277